Regeneron's stock rallies toward a record after profit, revenue beat expectations

Aberdeen Global Income Fund Inc.

Change company Symbol lookup

Select an option...

FCO Aberdeen Global Income Fund Inc.

DTEC ALPS Disruptive Technologies ETF

$RUIRETAILT Russell 1000 RGS Retail Total Return

BAC Bank of America Corp

MA Mastercard Inc

AAPL Apple Inc

AA Alcoa Corp

AMD Advanced Micro Devices Inc

PFE Pfizer Inc

MRNA Moderna Inc

Company profile

Aberdeen Global Income Fund, Inc. (the Fund) is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing primarily in fixed income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. The Fund invests in Government Bonds and Corporate Bonds. The Fund invests approximately 80% of its net assets, plus the amount of any borrowings for investment purposes, in debt securities. Approximately 60% of the Fund's total assets are invested in fixed income securities of issuers in Developed Markets or Investment Grade Developing Markets. The Fund invests approximately 40% of its total assets in fixed income securities of issuers in Developed Markets. Aberdeen Asset Management Limited is the investment advisor of the Fund. Its investment manager is Aberdeen Asset Management Asia Limited.

Regeneron's stock rallies toward a record after profit, revenue beat expectations

6:59 am ET August 5, 2020 (MarketWatch) Print

Shares of Regeneron Pharmaceuticals Inc. (REGN) ran up 3.2% toward a record high in premarket trading Wednesday, after the biotechnology company reported second-quarter profit and revenue that beat Wall Street expectations, and said it expects clinical studies to remain generally on track in the face of the COVID-19 pandemic. Net income rose to $897.3 million, or $7.61 a share, from $193.1 million, or $1.68 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $7.16, above the FactSet consensus of $5.91. Revenue rose to $1.95 billion from $1.58 billion, topping the FactSet consensus of $1.73 billion, as product sales and Sanofi collaboration revenue beat expectations, while Bayer collaboration revenue fell a bit shy. "We have advanced REGN-COV2, our antibody cocktail for COVID-19, into late-stage clinical studies in record time and are working to ensure supply is available later this year," said Chief Executive Leonard Schleifer. The stock has soared 72.7% year to date through Tuesday, while the S&P 500 has gained 2.3%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 05, 2020 06:59 ET (10:59 GMT)